SIFY- just went long

Just went long on SIFY @ 3.70. I would keep my eye on TCL too..

But as of now I think SIFY has taken enough beating and it is a money making company, so it will go back up.

The tag for LVLT is that SIFY does business with LVLT.

MDCO increasing volume and price push

Keep MDCO on watch or try to initiate small positions as it is potentially breaking through...to newer highs..

Volume has been well above average last two trading days (this post written on Feb 2) and price is on up swing.

Disclosure: Long

Facebook about IPO.. business comparison vs Google

Facebook filed for IPO recently and will go public in a little while.

Now to the numbers:
Facebook reports that it has about 845 million users. I would like to add a footnote to that. That should be 845 millions user accounts. I know several people who had created multiple accounts during the initial phase when fb let each email address to create an account.

Second, Facebook reports that it made $4.3 Billion. That translates to roughly $ 5.2 per user. Google, on the other hand reports $ 30 per user. Of course, I am slightly skeptical of that number too, but for what it's worth Google has been making real money for years now.

Third, Facebook's voting shares, will be controlled to over 56% by Mark Zuckenberg, the CEO. That leaves no powers in the hands of investors who would be putting in hard earned new money in..

So, I will be staying clear of Facebook because I see it as a gamble where I don't know the odds. I might as well as play that money in Santa Anita or the Kentucky Derby.. and have fun in the process.

ACTC Advanced Cell Technology Inc Advances on positive results

ACTC.OB a penny stock featured on this blog last year made some big advances Monday Jan 23, 2012, after preliminary findings of a study using Embryonic stem cells for the treatment of macular eye degeneration showed some positive findings.

The medical article is linked here (pdf) (fair use)

The excerpts from the discussion are:

We provide clinical evidence suggesting that
hESC-derived cells might be safely transplanted into
human patients (panel). In our study, we transplanted a
low dose (5×10⁴ cells) of RPE cells generated from hESCs
into one eye of two patients with different forms of
macular degeneration.

Our study is designed to test the safety and tolerability of hESC-RPE in patients with advanced-stage Stargardt’s macular dystrophy and dry age-related macular degeneration.

So far, the cells seem to have transplanted into both patients without abnormal proliferation, teratoma formation, graft rejection, or other untoward pathological reactions or safety signals. Continued follow-up and further study is needed. The ultimate therapeutic goal will be to treat patients earlier in the disease processes, potentially increasing the likelihood of photoreceptor and central visual rescue.

and the NY times article is available here.

Excerpts:
Both patients, who were legally blind, told researchers that they had gains in eyesight that were meaningful for them. One said she could see colors better and was able to thread a needle and sew a button for the first time in years. The other said she was able to navigate a shopping mall by herself.Still, it is hard to judge much from only two patients, especially when there was no control group given a placebo treatment.Indeed, Dr. Schwartz said that the improvement in vision of the woman who could go to the mall might have been a placebo effect, though he thought the improvement in the other patient did result from the implanted cells.Yet another reason to be cautious is that Advanced Cell Technology has had a reputation for publicizing its positive work, in part because it has often been on the brink of insolvency.

So, the key thing to keep in mind is that this is still a speculative stock, so be careful but be willing to take risks - like we did a year ago :)

Biotech: New Positions Initiated

Dynavax (DVAX) initiated at 3.32 on Friday Jan 6th, 2012 and closed at 3.62 for small profit. But might get back in using $5 Apr or July calls options.

INCY - initiated again at 16 for long term hold after some back and forth trading between 13.80 and 15. Missed the move from high 14's to the 16 due to lack of cash flow!! arggh!

Other stocks (no positions but good hopes): VRTX.


Current holds: MDCO (worth adding more in 18.50 to 19.20 range). LONG!!!